Today's Date: June 5, 2023
Operation Homefront presents Cornerstone Award to Bob Deforge of Pratt & Whitney   •   Cupshe Celebrates 8th Birthday with Exclusive Collection in Collaboration with Chanel Iman, Heather Rae El Moussa, and Brittany   •   New Web Addresses Pave the Way for LGBTQ+ Businesses to Thrive and Connect   •   Dr. Jen Ashton's "BETTER" Hits Newsstands Nationwide Today   •   The Executive Leadership Council Announces the Appointment of Fabian Milburn as Chief Legal and Human Resources Officer   •   Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bron   •   Statement by the Prime Minister on Canadian Armed Forces Day   •   Lexington Law to Continue Fighting for Clients That Seek Credit Reports That are Fair, Accurate and Supported by Evidence   •   Sustainability as a Success Factor: OQ Chemicals Launches Biobased Oxbalance TCD Alcohol DM   •   Tips for a smooth transition to senior living from the San Luis Obispo assisted living professionals   •   Seneca Therapeutics, Inc. Appoints Cuong Do to its Board of Directors   •   CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with N   •   Founders First Capital Partners Sponsors Women in Cloud to Foster Financial Opportunities for Women Tech Founders   •   U.S. Institute of Peace Opens Nominations for 2023 Women Building Peace Award   •   Expro Wins Well Intervention and Integrity Contract for Major Project in Uganda   •   Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination wi   •   DANA and Ant Group Announce Local Women Entrepreneur Winners of the Inaugural SisBerdaya Program   •   Anaergia Signs Contract to Build State-of-the-Art Food Waste and Wastewater Sludge Co-Digestion Facility at Monterey One Water i   •   Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives   •   Brand Strength Assumes Greater Importance for Private Equity Firms as Competition for Deals and LP Dollars Intensifies
Bookmark and Share

Pragma Bio Secures $10M From The Venture Collective, Merck Global Health Innovation Fund, Viking Global, and CJ Investments To E

SOUTH SAN FRANCISCO, Calif. , March 23 /Businesswire/ - Pragma Bio, the technology-enabled platform for drug discovery formerly known as VastBiome, announced it has raised an additional $10 million in equity to continue its development of proprietary methods in genomic sequencing, artificial intelligence and synthetic biology to discover biomarkers and novel therapeutics to treat immunologic disorders.

The Venture Collective, led the round joined by investors Viking Global Investors, Merck Global Health Innovation Fund and CJ Investments (Korean-based strategic investor). The round brings the company’s total venture backing to $15 million.

Pragma Bio is utilizing patient data to explore the synergistic bond between nature's chemistry found in the human body and the immune system with the goal of discovering novel medicines. The new funding will help the company expand its operations, increase product development, and recruit new team members to fuel Pragma Bio’s growth.

"The infusion of funding reflects our goal of unveiling the symbiotic relationship between nature and the human body, enabling us to create natural medicines that foster our well-being," said Kareem Barghouti, the CEO of Pragma Bio. “The participation of world-class healthcare investors is a validation of our approach, which is aimed at uncovering medicines naturally produced within our bodies every day. Patients are waiting for better options, and Pragma Bio will offer them,” he added.

Pragma Bio has created a hypothesis generating discovery engine called Lattice, which archives and sorts through countless interactions and correlations between natural products and human cells that are linked to clinical outcomes. Biologically significant microbial genes are subsequently manipulated and transferred to the laboratory, utilizing state-of-the-art technology to produce and manifest a collection of enzymes and natural chemistries. The company has already gained considerable momentum in discovering immuno-oncology biomarkers and facilitating scalable enzyme expression. Pragma Bio has also established academic and pharmaceutical partnerships with global leaders. Furthermore, Pragma Bio has assembled a team of world-renowned drug hunters that have successfully generated over $30 billion in exits and commercialized medicines. Together, they bring a wealth of expertise to the table, working hand in hand with highly experienced data scientists, chemists and biologists driving the development of the therapeutics platform.

Nick Shekerdemian, Founding Partner of The Venture Collective said "We truly believe that the natural world holds so much potential for treating diseases that lack good therapeutic options. We are excited to work with the outstanding team at Pragma to bridge the gap between natural products and rationally designed therapeutics in order to improve the lives of patients everywhere."

Prem Tumkosit, Managing Director of the Merck Global Health Innovation Fund (GHIF) said “GHIF made its initial investment in Pragma Bio in 2020 out of our Next Horizon investment area, which focuses on ground breaking technologies.” Adding that "We're thrilled to continue our support for Pragma Bio in this financing.”

The name Pragma Bio encapsulates the company's mission holistically. In computer programming, pragma refers to a compiler directive that transforms program code into executable actions, effectively bringing the code to life. Pragma Bio is built upon the concept of bringing program code and genetic code to life in a pragmatic fashion.

About Pragma Bio:

Pragma Bio is a tech-enabled therapeutics company creating the first-of-its-kind-map of chemicals designed by nature, housed in humans, and linked to immune-related health outcomes. Pragma Bio is forging into uncharted territory, leveraging the most advanced technologies in machine learning and synthetic biology to scale intelligent discovery with iterative biomanufacturing in the pursuit of novel enzymes and their respective novel chemistries with strong biological signals and desirable therapeutic properties. Pragma Bio is dedicated to developing innovative solutions to bring life-changing medicines to patients through internal efforts and trusted partners. For more information on Pragma Bio, visit

STORY TAGS: United States, North America, Health, Technology, Software, General Health, Research, Science, Pharmaceutical, California, Funding, Product/Service,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News